Compass Pathways Achieves Phase 3 Win for Psilocybin in Depression, Yet Stock Tumbles

Compass Pathways; COMP360; psilocybin; Phase 3 trial; depression; treatment-resistant depression; clinical trial; stock decline; investor reaction; FDA

Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate

diabetes; obesity; pharmaceutical sales; Eli Lilly; Novo Nordisk; Evaluate report; top-selling drugs; tirzepatide; semaglutide; Mounjaro; Zepbound; Ozempic; Wegovy; CagriSema; 2030 forecast